comprehensive -WSS

comprehensive

author：explore 2025-10-01 00:45:48 - browse：94776

Illustration of a bear on a red arrow with a bull underneath pushing the arrow upward. -- biotech coverage from STAT — Adobe

This was supposed to be the year of the biotech comeback, when promising new medicines and high-dollar buyouts would reverse a sector-wide slump that dates back to 2021. Instead, biotech stocks have dramatically underperformed the broader market, and the year’s few green shoots are yet to grow into a turnaround.

The closely watched XBI biotech index has fallen more than 10% in 2023, while the S&P 500 rose about 13% in the same period. Privately held companies have struggled to raise new capital without taking a hit to their valuations, and biotech IPOs have been rare in number and inconsistent in return.

The problem, analysts and investors said, is that the generalist investors who steer trillions of dollars of capital have simply soured on biotech. The furor over novel weight loss medicines like Wegovy has largely been a Big Pharma phenomenon, and rising interest rates have steered fund managers away from risky biotech stocks. The sector has gone through boom and bust cycles in the past, and it’s difficult, if not impossible, to predict when the macro winds might change and make biotech as popular as it was in the early days of Covid-19.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： State Dept. review finds Biden bears some blame for Afghanistan failures
Next article： Medicare Advantage today, explained in one chart

entertainment

WSS

Addiction experts warn against a second 'war on drugs'

Bird flu: Don't repeat Covid's 'health versus the economy' framing

New brain studies show LSD's effects on the brain in full color

Parkinson’s finding may lead to tests and, someday, treatments

How digital therapeutics firms are pivoting after Pear's bankruptcy

eGenesis tests gene

explore

comprehensive

focus

Cancer drug shortages should be causing more outrage

It's time to retire 'poor historian' from clinicians' vocabularies

How to save PrEP access — and even expand it

Francis Collins on trust in science and how Covid communications failed

ChatGPT in medicine: STAT answers readers' burning questions

It's time to retire 'poor historian' from clinicians' vocabularies

Drug repurposing or repositioning? The language matters

NIH director takes cautious approach to Biden drug pricing priority

Medical records are filled with copy

Dewpoint Therapeutics lays off staff after losing partnerships

hotspot

Humana cuts profit projections as Medicare Advantage costs soar

How a billionaire couple greased the skids for Pelosi’s drug pricing bill

EU regulator recommends expanding Mounjaro approval to obesity

Second House panel advances two

Criminal prosecution for violating HIPAA: an emerging threat

Readout Newsletter: BridgeBio, Madrigal, and Silicon Valley Bank

entertainment

explore

hotspot

leisure time